Global Custom Market Research Reports Provider Company

phone

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2018 in Pharmaceuticals

  • Published Date: 01 Aug 2018
  • Number of Pages: 79
  • Category: Pharmaceuticals
  • Country: Global
Partnerships, Licensing, Investments and M&A Deals and Trends for April 2018 in Pharmaceuticals

Summary

GlobalDatas "Partnerships, Licensing, Investments and M&A Deals and Trends for April 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2018. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and womens health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Publisher Name : GlobalData

2
1.1 List of Tables 5
1.2 List of Figures 7
2 Pharmaceuticals & Healthcare, Global, Deal Summary, 10
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, April 2018 10
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, April 2018 12
2.2.1 GlaxoSmithKline to Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 12
2.2.2 Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 13
2.2.3 Sanofi Prices Public Offering Notes for USD9.9 Billion 13
2.2.4 Platinum Equity to Acquire LifeScan from Johnson & Johnson for USD2.1 Billion 13
2.2.5 Valeant Pharma Prices Private Placement of 9.25% Senior Notes Due 2026 for USD1.17 Billion 14
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, April 2018 15
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, April 2018 16
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17
3.1 Pharmaceuticals & Healthcare, Global, M&A, April 2018 17
3.1.1 Top M&A Deals in April 2018 18
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, November 2017 - April 2018 18
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, April 2018 20
3.2.1 Top Equity Offering Deals in April 2018 21
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, November 2017 - April 2018 22
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, April 2018 23
3.3.1 Top PE/VC Deals in April 2018 24
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, April 2018 25
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, April 2018 26
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016-April 2018 28
3.3.7 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016-April 2018 29
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2018 30
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, November 2017 - April 2018 31
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), April 2018 32
3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, April 2018 33
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2017 - April 2018 34
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, November 2017 - April 2018 36
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), November 2017 - April 2018 37
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2017 - April 2018 38
4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2018 39
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2018 39
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2018 40
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), November 2017 - April 2018 41
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), November 2017 - April 2018 42
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), November 2017 - April 2018 43
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), November 2017 - April 2018 45
4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, April 2018 46
4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, April 2018 46
4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, April 2018 47
5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 48
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, April 2018 48
5.1.1 Oncology - Deals of the Month 49
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, April 2018 51
5.2.1 Central Nervous System - Deals of the Month 52
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, April 2018 54
5.3.1 Infectious Diseases - Deals of the Month 55
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, April 2018 57
5.4.1 Cardiovascular - Deal of the Month 58
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, April 2018 59
5.5.1 Immunology - Deals of the Month 60
5.6 Pharmaceuticals & Healthcare, Global, Respiratory Deals, April 2018 62
5.6.1 Respiratory - Deal of the Month 63
5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, April 2018 64
5.7.1 Metabolic Disorders - Deals of the Month 65
6 Deal Summary by Geography 66
6.1 Pharmaceuticals & Healthcare, North America Deals, April 2018 66
6.1.1 North America - Deals of the Month 67
6.2 Pharmaceuticals & Healthcare, Europe, Deals, April 2018 68
6.2.1 Europe - Deals of the Month 69
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, April 2018 71
6.3.1 Asia-Pacific - Deals of the Month 72
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, April 2018 73
6.4.1 Rest of the World - Deals of the Month 74
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 75
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, November 2017 - April 2018 75
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, November 2017 - April 2018 76
8 Further Information 77
8.1 Methodology 77
8.2 About GlobalData 78
8.3 Contact Us 78
8.4 Disclosure information 78
8.5 Disclaimer 79

List Of Tables


Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 11
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, April 2018 12
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), April 2018 16
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 17
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, April 2018 18
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2017 - April 2018 19
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 21
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, April 2018 21
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 22
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 24
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, April 2018 24
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, November 2017 - April 2018 25
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), April 2018 27
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 28
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2017 - April 2018 29
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 30
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 31
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2017 - April 2018 32
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), April 2018 33
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2017 - April 2018 35
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2017 - April 2018 37
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), November 2017 - April 2018 38
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 39
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), November 2017 - April 2018 40
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 41
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), April 2018 42
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2017 - April 2018 44
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2018 46
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, April 2018 46
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, April 2018 46
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, April 2018 47
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 49
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 52
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 55
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 58
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 60
Table 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 63
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 65
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 67
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 69
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 72
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 74
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 75
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 76

List Of Figures


Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 10
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), April 2018 15
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), April 2018 16
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 17
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2017 - April 2018 18
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 20
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 22
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 23
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2017 - April 2018 25
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), April 2018 26
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), April 2018 27
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 28
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 30
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 31
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2017 - April 2018 32
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2017 - April 2018 34
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2017 - April 2018 36
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2017 - April 2018 37
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2017 - April 2018 38
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 39
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2017 - April 2018 40
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 41
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2017 - April 2018 42
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, November 2017 - April 2018 43
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), November 2017 - April 2018 44
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), April 2018 45
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 48
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 51
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 54
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 57
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 59
Figure 32: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 62
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 64
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 66
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 68
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 71
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 73
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 75
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2017 - April 2018 76

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2018 in Pharmaceuticals GlobalDatas Partnerships, Licensing, Investments and M&A Deals and Trends for June 2018 in Pharmaceuticals report is an essential

View Report

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2018 in Pharmaceuticals GlobalDatas Partnerships, Licensing, Investments and M&A Deals and Trends for May 2018 in Pharmaceuticals report is an essential

View Report

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2018 GlobalDatas Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2018 , report is an essential

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports